DEFIBROTIDE 200 MG INJECTION
Defibrotide sodium is an oligonucleotide mixture with profibrinolytic properties. The chemical name of defibrotide sodium is polydeoxyribonucleotide, sodium salt. Defibrotide sodium is a polydisperse mixture of predominantly single-stranded (ss) polydeoxyribonucleotide sodium salts derived from porcine intestinal tissue having a mean weighted molecular weight of 13-20 kDa, and a potency of 27-39 and 28-38 biological units per mg as determined by two separate assays measuring the release of a product formed by contact between defibrotide sodium, plasmin and a plasmin substrate. DEFITELIO (defibrotide sodium) injection is a clear, light yellow to brown, sterile, preservative-free solution in a
single-patient-use vial for intravenous use. Each milliliter of the injection contains 80 mg of defibrotide sodium and
10 mg of Sodium Citrate, USP, in Water for Injection, USP. Hydrochloric Acid, NF, and/or Sodium Hydroxide, NF,
may have been used to adjust pH to 6.8-7.8.
200 mg/2.5 mL (80 mg/mL) in a single-patient-use vial
As per Recommendation by Company:
*Administer DEFITELIO 6.25 mg/kg every 6 hours given as a 2-hour
intravenous infusion.
* Treat for a minimum of 21 days. If after 21 days signs and symptoms of
VOD have not resolved, continue treatment until resolution.
DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
